Equities analysts expect ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) to post earnings per share (EPS) of ($0.09) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for ContraVir Pharmaceuticals’ earnings. ContraVir Pharmaceuticals posted earnings of ($0.16) per share during the same quarter last year, which indicates a positive year over year growth rate of 43.8%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, September 27th.

On average, analysts expect that ContraVir Pharmaceuticals will report full-year earnings of ($0.41) per share for the current fiscal year. For the next financial year, analysts anticipate that the business will report earnings of ($0.41) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow ContraVir Pharmaceuticals.

Several equities research analysts recently weighed in on the stock. Maxim Group set a $4.00 price objective on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Noble Financial reiterated a “buy” rating on shares of ContraVir Pharmaceuticals in a research note on Friday, April 21st.

ILLEGAL ACTIVITY NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/07/contravir-pharmaceuticals-inc-ctrv-expected-to-announce-earnings-of-0-09-per-share-updated-updated-updated.html.

Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) traded up 2.177% during trading on Wednesday, reaching $0.568. The company had a trading volume of 366,855 shares. The stock’s market capitalization is $36.19 million. The stock has a 50 day moving average of $0.65 and a 200 day moving average of $1.23. ContraVir Pharmaceuticals has a 52-week low of $0.54 and a 52-week high of $2.65.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Teachers Advisors LLC raised its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 3.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 298,781 shares of the biopharmaceutical company’s stock after buying an additional 8,862 shares during the period. Teachers Advisors LLC owned approximately 0.48% of ContraVir Pharmaceuticals worth $1,820,000 as of its most recent SEC filing. 6.45% of the stock is owned by institutional investors and hedge funds.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (CTRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.